Drug intelligence / Profile preview

CDED + penicillin

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

CDED + penicillin is a combination therapy approach for inflammatory bowel disease (IBD), particularly Crohn's disease, that combines the Crohn's Disease Exclusion Diet (CDED) with penicillin-class antibiotics. This approach aims to manage gut inflammation and dysbiosis through dietary modification while using antibiotics to target specific bacterial populations. Penicillin antibiotics, such as amoxicillin, are often used in combination with other antibiotics for refractory IBD cases.

Other names: Crohn's Disease Exclusion Diet with penicillin

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on CDED + penicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDED + penicillin.

Explore the full profile